Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A. Douangamath, D. Fearon, Paul Gehrtz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

The SARS-CoV-2 main protease as drug target
Sven Ullrich, Christoph Nitsche
Bioorganic & Medicinal Chemistry Letters (2020) Vol. 30, Iss. 17, pp. 127377-127377
Open Access | Times Cited: 719
A critical overview of computational approaches employed for COVID-19 drug discovery
Eugene Muratov, Rommie E. Amaro, Carolina Horta Andrade, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 16, pp. 9121-9151
Open Access | Times Cited: 180
Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays**
Tarick J. El‐Baba, Corinne A. Lutomski, A.L. Kantsadi, et al.
Angewandte Chemie International Edition (2020) Vol. 59, Iss. 52, pp. 23544-23548
Open Access | Times Cited: 129
Crowdsourcing drug discovery for pandemics
John D. Chodera, Alpha A. Lee, Nir London, et al.
Nature Chemistry (2020) Vol. 12, Iss. 7, pp. 581-581
Open Access | Times Cited: 109
Folding@home: Achievements from over 20 years of citizen science herald the exascale era
Vincent A. Voelz, Vijay S. Pande, Gregory R. Bowman
Biophysical Journal (2023) Vol. 122, Iss. 14, pp. 2852-2863
Open Access | Times Cited: 41
Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design
Franz‐Josef Meyer‐Almes
Computational Biology and Chemistry (2020) Vol. 88, pp. 107351-107351
Open Access | Times Cited: 67
The rise of molecular simulations in fragment-based drug design (FBDD): an overview
Maicol Bissaro, Mattia Sturlese, Stefano Moro
Drug Discovery Today (2020) Vol. 25, Iss. 9, pp. 1693-1701
Open Access | Times Cited: 58
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir
Giovanni Bolcato, Maicol Bissaro, Matteo Pavan, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 54
Disulfide Bonds Play a Critical Role in the Structure and Function of the Receptor-binding Domain of the SARS-CoV-2 Spike Antigen
Andrey M. Grishin, Natalia V. Dolgova, Shelby Landreth, et al.
Journal of Molecular Biology (2021) Vol. 434, Iss. 2, pp. 167357-167357
Open Access | Times Cited: 53
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Ying Li Weng, Shiv Rakesh Naik, Nadia Dingelstad, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 52
The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2
Zhenming Jin, Haofeng Wang, Yinkai Duan, et al.
Biochemical and Biophysical Research Communications (2020) Vol. 538, pp. 63-71
Open Access | Times Cited: 43
Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists
Sheng Zhang, Maj Krumberger, Michael A. Morris, et al.
European Journal of Medicinal Chemistry (2021) Vol. 218, pp. 113390-113390
Open Access | Times Cited: 36
A cyclic peptide inhibitor of the SARS-CoV-2 main protease
Adam G. Kreutzer, Maj Krumberger, Elizabeth M. Diessner, et al.
European Journal of Medicinal Chemistry (2021) Vol. 221, pp. 113530-113530
Open Access | Times Cited: 35
Discovery and Clinical Development of Ensitrelvir: An Oral SARS‐CoV‐2 3CL Protease Inhibitor for the Treatment of COVID‐19

(2025), pp. 365-388
Closed Access
COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning
The COVID Moonshot Consortium, John D. Chodera, Alpha A. Lee, et al.
(2020)
Open Access | Times Cited: 31
Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations
Jacek Haneczok, Marcin Delijewski
Journal of Biomedical Informatics (2021) Vol. 119, pp. 103821-103821
Open Access | Times Cited: 22
Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease
Ànna Pavlova, Diane L. Lynch, Isabella Daidone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 21
Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking
M. Schuller, G.J. Correy, Stefan Gahbauer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 19
An expanded view of ligandability in the allosteric enzyme PTP1B from computational reanalysis of large-scale crystallographic data
Tamar Mehlman, Helen M. Ginn, D.A. Keedy
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
In Silico and In Vitro Studies of Terpenes from the Fabaceae Family Using the Phenotypic Screening Model against the SARS-CoV-2 Virus
Natália Ferreira de Sousa, Gabrielly Diniz Duarte, Carolina Borsoi Moraes, et al.
(2024)
Open Access | Times Cited: 1
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor
Daniel Zaidman, Paul Gehrtz, Mihajlo Filep, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 11
Inhibition of SARS-CoV-2 main protease: a repurposing study that targets the dimer interface of the protein
Hanife Pekel, Metehan Ilter, Özge Şensoy
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 15, pp. 7167-7182
Open Access | Times Cited: 10
A REVIEW ON COVID-19 PANDEMIC A GLOBAL THREAT-CURRENT STATUS AND CHALLENGES AND PREVENTIVE STRATEGIES
S. Sukumaran, S. Sathianarayanan
International Journal of Applied Pharmaceutics (2021), pp. 10-14
Open Access | Times Cited: 9
Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays**
Tarick J. El‐Baba, Corinne A. Lutomski, A.L. Kantsadi, et al.
Angewandte Chemie (2020) Vol. 132, Iss. 52, pp. 23750-23754
Open Access | Times Cited: 9
Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease
Adam G. Kreutzer, Maj Krumberger, Chelsea Marie T. Parrocha, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top